Eli Lilly Presents Real-World Evidence for Kisunla in Early Alzheimer's Disease

Eli Lilly today presented real-world evidence from the open-label extension of the TRAILBLAZER-ALZ 2 trial showing that Kisunla (donanemab-azbt) maintains clinical benefits in patients with early Alzheimer's disease. The data showed that patients who achieved complete amyloid clearance and stopped treatment maintained their clinical benefits for up to 18 months after treatment discontinuation.